What's in Sinocelltech Ltd.'s pipeline?

Sinocelltech Ltd. has 33 drugs in our index: 1 marketed, 0 filed, 9 in Phase 3, 15 in Phase 2, 8 in Phase 1.

Which companies overlap with Sinocelltech Ltd.'s portfolio?

Top competitors by shared drug class: AltruBio Inc., Beijing Yongtai Ruike Biotechnology Company Ltd, Bristol-Myers Squibb, Celgene, Celyad Oncology SA.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sinocelltech-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Sinocelltech Ltd. — Portfolio Competitive Intelligence Brief

Sinocelltech Ltd. pipeline: 1 marketed, 0 filed, 9 Phase 3, 15 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 9 Phase 3 15 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Recombinant Human Coagulation FVIII	Recombinant Human Coagulation FVIII	marketed	Coagulation factor replacement therapy	Coagulation Factor VIII	Hematology
SCTB14	SCTB14	phase 3	CD47/SIRPα axis inhibitor	CD47/SIRPα axis	Oncology
SCTC21C	SCTC21C	phase 3	CAR-T cell therapy		Oncology
Placebos+chemo	Placebos+chemo	phase 3			Oncology
SCT-I10A+chemo	SCT-I10A+chemo	phase 3			Oncology
Rituximab plus CHOP	Rituximab plus CHOP	phase 3	Monoclonal antibody and chemotherapy regimen	CD20	Oncology
SCT510A	SCT510A	phase 3	Natural killer cell therapy		Oncology
SCTV01E	SCTV01E	phase 3	CAR-T cell therapy		Oncology
SCT630	SCT630	phase 3
SCT400 plus CHOP	SCT400 plus CHOP	phase 3	BCL-2 inhibitor, Chemotherapy	BCL-2	Oncology

Therapeutic area mix

Oncology · 8
Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AltruBio Inc. · 1 shared drug class
Beijing Yongtai Ruike Biotechnology Company Ltd · 1 shared drug class
Bristol-Myers Squibb · 1 shared drug class
Celgene · 1 shared drug class
Celyad Oncology SA · 1 shared drug class
Chongqing Precision Biotech Co., Ltd · 1 shared drug class
City of Hope Medical Center · 1 shared drug class
Akeso · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sinocelltech Ltd.:

Cite this brief

Drug Landscape (2026). Sinocelltech Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sinocelltech-ltd. Accessed 2026-05-15.